Eisai has announced the launch of Fycompa (perampanel) in Spain, where it is indicated for the adjunctive treatment of partial-onset seizures, with or without secondary generalised seizures, in patients with epilepsy aged 12 years and older. The launch follows approval for reimbursement, which was based on three randomised, double-blind, placebo-controlled and dose-escalated global pivotal Phase III studies (304, 305, and 306), as well as an open-label extension study (307).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,958 JPY | +0.46% | +7.41% | -1.33% |
07-12 | Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel | CI |
07-11 | Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.33% | 12.6B | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+17.90% | 228B | |
+14.86% | 177B | |
+0.45% | 164B |
- Stock Market
- Equities
- 4523 Stock
- News Eisai Co., Ltd.
- Eisai Launches Fycompa in Spain